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Abstract 
 
Background: WHO recommends differentiated antiretroviral therapy (ART) delivery with longer visit 
intervals for clinically stable patients. We examined time trends in visit frequency and associations 
between criteria for clinical stability and visit frequency in ART programs in Southern Africa. 
Methods: We included adults on ART from four programs with viral-load monitoring, two programs 
with CD4 monitoring, and four programs with clinical monitoring of ART. We classified patients as 
clinically stable based on virological (viral load <1000 copies/mL), immunological (CD4 >200 cells/µL), 
or clinical (no current tuberculosis) criteria. We used Poisson regression and survival models to 
examine associations between criteria for clinical stability and the rate of clinic visits. 
Results: We included 180,837 patients. There were trends towards fewer visits in more recent years 
and with longer ART duration. In all ART programs, clinically stable patients were seen less frequently 
than patients receiving failing ART, but the strengths of the association varied. Adjusted incidence-
rate ratios (IRRs) comparing visit rates for stable patients with patients on failing ART were 0.82 (95% 
CI 0.73-0.90) for patients classified based on the virological criterion, 0.81 (0.69-0.93) for patients 
classified based on the clinical criterion, and 0.90 (0.85-0.96) for patients classified based on the 
immunological criterion for stability.  
Conclusion: Differences in visit rates between stable patients and patients failing ART were variable 
and modest overall. Larger differences were seen in programs using virological criteria for clinical 
stability than in programs using immunological criteria. Greater access to routine viral-load 
monitoring may increase scale-up of differentiated ART delivery. 
Keywords: HIV, differentiated antiretroviral therapy delivery, differentiated service delivery, 
differentiated care, stable patients, Africa.
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Introduction 
Since 2015 the World Health Organization (WHO) has recommended treating all people living with 
HIV, and today more than 20 million people are on antiretroviral therapy (ART) with the goal to 
expand ART to reach about 30 million by 2020.1–4 WHO’s 2016 HIV treatment guidelines recommend 
a differentiated care approach to meet the needs of a rapidly growing and increasingly diverse cohort 
of people on ART.2 Differentiated care is a public health approach to adapting service delivery to 
patient needs.2,5,6 Differentiated care has been widely adopted by countries with support from major 
donors including PEPFAR, the Global Fund, and the Bill & Melinda Gates Foundation.7–9  
Differentiated appointment spacing, i.e. extending visit intervals for clinically stable patients to 3-6 
months, is one of the key recommendations for differentiated care.2 National guidelines of several 
Southern African countries introduced extended visit intervals for patients stable on ART long before 
this recommendation was adopted by WHO in 2016. For example, the 2004 South African National 
Antiretroviral Treatment Guidelines recommended that stable patients should be seen every 3 
months.10 In Malawi, 2-monthly follow-up visits for stable patients were introduced in 2006.11  
HIV programs need simple and reliable criteria for identifying clinically stable patients to implement 
differentiated care models safely and effectively. Early versions of national treatment guidelines did 
not define criteria for clinical stability.10,11 WHO 2017 criteria for defining clinically stable patients 
include receiving ART for at least one year, no adverse drug reactions, no current illness, a good 
understanding of lifelong adherence, and evidence of treatment success. Programs with routine viral-
load monitoring are advised to use virological criteria as a marker of treatment success (i.e. two 
consecutive viral-load measurements below 1000 copies/mL), and programs with CD4 monitoring 
should use immunological criteria (i.e. rising CD4 cell counts or a CD4 cell count >200 cells/µL).5,12 
Programs without access to viral load or CD4 monitoring rely on clinical criteria to determine 
treatment success.13,14   
We examined time trends in visit frequency in ART programs in Southern Africa from 2004 to 2017 to 
describe the scale-up of extended visit intervals. We studied associations between visit frequency 
and clinical, immunological, and virological criteria for clinical stability to explore whether health care 
workers used available monitoring tools to identify patients who could be seen less frequently.   
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Methods 
Antiretroviral therapy programs 
The International epidemiology Databases to Evaluate AIDS (IeDEA) is a global collaboration of ART 
programs. We included 10 ART programs that participate in the Southern African region of IeDEA 
(IeDEA-SA).15 Data were collected at ART initiation (baseline) and each follow-up visit using 
standardized instruments. ART programs regularly transfer datasets to data centers at the 
Universities of Cape Town, South Africa, and Bern, Switzerland for data curation and statistical 
analysis. ART programs vary in size: some programs like Tygerberg or Lighthouse operate at one or 
two large urban clinics while other programs like CIDRZ support over 300 urban and rural clinics in 
several districts. Four cohorts from South Africa performed routine viral-load monitoring with viral-
load testing and CD4 cell counts measured annually. In two programs from Zambia and Zimbabwe, 
patient monitoring was based mainly on annual CD4 cell counts, and viral loads were not routinely 
monitored. In four programs from Lesotho, Malawi, Mozambique, and Zimbabwe, monitoring was 
mainly based on clinical criteria.16 
Outcomes and definitions  
Our primary outcome was the rate of clinic visits. A clinic visit was defined as attendance at a health 
facility for clinical assessment or pharmacy refill. Gaps between visits longer than one year were 
regarded as unscheduled treatment interruptions. Programs were classified as viral-load monitoring 
programs if the majority of their patients had a viral load measured during the first year on ART. 
Programs that measured the CD4 cell count for the majority of their patients during the first time on 
ART were classified as using CD4 monitoring. All other programs were deemed to be using clinical 
monitoring. 
Clinical stability was defined according to WHO’s 2017 criteria.5,6 We classified patients as clinically 
stable if they received ART for at least one year and met a criterion for clinical stability. We used a 
different criterion for clinical stability for each monitoring strategy: in programs with viral-load 
monitoring, we classified patients with a viral load of <1000 copies/mL as clinically stable; in 
programs with CD4 monitoring, patients with a CD4 cell count of >200 cells/µL were deemed 
clinically stable; and in programs using clinical monitoring, patients without current tuberculosis 
were classified as stable. Our definition of clinical stability in programs using clinical monitoring relied 
solely on diagnosis of tuberculosis because we had no data on symptoms of other HIV-related 
diseases or side effects. Patients on ART for at least one year who did not meet the criterion for 
clinical stability were classified as receiving a failing ART regimen. Clinical stability was defined as a 
time-varying covariate carried forward until a next laboratory measurement or OI start or end date 
was recorded. We categorized visit dates into four periods: calendar years 2004-2007, 2008-2011, 
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2012-2015, and 2016-2017. We used WHO criteria to define clinical stage.17 We defined CD4 count at 
ART initiation as the value closest to the date of ART initiation within three months prior to and one 
month after initiation. CD4 cell counts were grouped into <200 cells/µL, 200-349 cells/µL, 350-500 
cells/µL, and >500 cells/µL. Age at ART initiation was grouped into 16-24 years, 25-34 years, 35-49 
years, and 50 years or older. Viral load at ART initiation was defined as the value closest to the date 
of ART initiation within six months before and seven days after ART initiation. Time on ART was 
categorized in years: 1, 2, 3, 4, and 5-10.  
 
Participants 
HIV-1 infected patients aged ≥16 years who initiated ART between January 2004 and September 
2017 and had at least one visit after the first year of ART were eligible for analysis. We excluded 
patients with insufficient data to define clinical stability by 12 months on ART (i.e. patients from 
programs with viral-load monitoring without a viral-load measurement between 4-12 months after 
ART initiation, and patients from programs with CD4 monitoring without CD4 cell count 
measurement between 3-12 months after ART initiation) (Figure 1). 
Statistical analysis 
We used summary statistics to described characteristics of patients at ART. We estimated incidence-
rate ratios (IRRs) and 95% confidence intervals (CI) for predictors of visit frequency using univariable 
and multivariable Poisson regression models. In Poisson regression, each visit represents an event 
and the time between two consecutive visits is the exposure time. We used robust standard errors to 
adjust for clustering of visits at the patient level. Patients were followed from one year after initiation 
of ART for up to 10 years. We examined the following predictors: calendar year, time on ART, CD4 
cell count, WHO clinical stage and age at ART initiation, and treatment program. Calendar year and 
time on ART were assessed at each visit and modelled as time-varying covariates. We added a 
continuous predictor for the proportion of patients receiving efavirenz-based ART at a program to 
assess whether the use of less toxic regimen explained the relationship between calendar year and 
visit frequency.  
We modelled associations between criteria for clinical stability and visit frequency in two steps to 
account for the heterogeneity between ART programs. We first ran multivariable Poisson regression 
models and estimated adjusted IRRs and 95% CIs for the effect of clinical stability on visit frequency 
in each ART program. Models adjusted for time on ART, CD4 cell count, WHO clinical stage and age at 
ART initiation, and calendar year. We then pooled IRRs by criterion for clinical stability using random 
effects meta-analysis. We present adjusted IRRs for the difference in the rate of visits between stable 
patients and patients failing ART in each treatment program in a forest plot. 
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Finally, we used multivariable flexible parametric survival analysis to examine time-dependent 
effects of clinical stability on the visit rate (i.e. varying effects of clinical stability over time on ART) 
and to show absolute differences in the rate of visits between stable patients and patients receiving 
failing ART. In this survival analysis, each visit after ART initiation represents a failure event and 
multiple visits per patient are treated as multiple failures. Patients remain at risk of experiencing 
subsequent events after failure. Each visit date after ART initiation marks the end of the previous 
time interval and the beginning of the next interval (i.e. gap between visits). We used Royston-
Parmar models with restricted cubic splines and interaction terms between restricted cubic splines 
and predictors for clinical stability to model time-dependent effects.18–20 We used robust standard 
errors to adjust for clustering of multiple failure events within patients. We ran separate models for 
each criterion for clinical stability and predicted and plotted adjusted hazard rates and 95% CIs for 
specific levels of covariates. Models included predictors for clinical stability, calendar year, CD4 cell 
count at ART initiation, age, gender, and treatment program. 
Missing WHO clinical stage and CD4 cell count at ART initiation were included as a separate category 
in all models. Unscheduled treatment interruptions (i.e. one year gaps) were excluded from analyses. 
In sensitivity analysis, we set the duration of these intervals to the median visit interval for the 
treatment program and time on ART. Statistical analysis was done in Stata (Version 15, Stata 
Corporation, College Station, TX, USA). 
Ethical considerations 
Local review boards and ethics committees for each treatment program that provided data approved 
the use of the data included in this study. The Cantonal Ethics Committee of the Canton of Bern, 
Switzerland, approved data merging and the collaborative analyses. Local review boards and the 
Cantonal Ethics Committee of the Canton of Bern waived the requirement to obtain informed 
consent.  
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Results 
Characteristics of patients and ART programs 
As shown in Table 1, we included 180,837 patients from 10 ART programs in seven countries: 38,045 
(21.0%) patients came from four programs with viral-load monitoring; 85,555 (47.3%) from two 
programs with CD4 monitoring; and 57,237 (31.7%) from six programs with clinical monitoring. In 
South African ART programs, EFV-based ART was used for at least half of patients since 2005. The 
proportion of patients receiving EFV-based ART increased further with the phase out of stavudin 
(d4T) in 2010-2011. Most other programs widely introduced EFV-based ART as standard first-line 
regimen in 2013-2014 (Figure S1). We followed patients from January 1, 2004 up to August 31, 2017 
for 876,801 person-years. Median follow-up time was 4.36 years (interquartile range [IQR] 2.55-
6.88). Median age at ART initiation was 35 years (IQR 30-42), and 117,240 (64.8%) of included 
patients were female. Median CD4 cell count at ART initiation was 171 cells/µL (IQR 91-264). Almost 
half of the patients with known WHO clinical stage (46.3%, 68,901 of 148,809 patients) initiated ART 
in stage 3 or 4. 
Predictors of visit frequency 
Table 2 shows unadjusted and adjusted IRRs for predictors of visit frequency in programs using viral-
load monitoring, CD4 monitoring, and clinical monitoring. There was a trend towards fewer visits in 
more recent years across all monitoring strategies. Rates of visits declined especially after 2011. 
Adjusted IRRs for the years 2012-2015 compared to years 2004-2007 were 0.75 (95% CI 0.75-0.76) in 
programs using viral-load monitoring, 0.54 (CI 0.54-0.55) in programs using CD4 monitoring, and 0.77 
(CI 0.76-0.78) in programs using clinical monitoring. Time on ART and treatment program were also 
associated with visit frequency. Age, gender, and WHO clinical stage at ART initiation were weakly 
associated with visit rate. In viral load and CD4 monitoring programs a higher CD4 cell counts at the 
start of ART was associated with a slightly lower visit frequently. Adjusted IRRs for the change in visit 
frequency per 100% increase in the proportion of patients receiving EFV-based ART were 0.64 (CI 
0.62-0.66) in programs using viral-load monitoring, 0.56 (CI 0.55-0.57) in programs using CD4 
monitoring, and 0.88 (CI 0.88-0.89) in programs using clinical monitoring. The proportion of patients 
receiving EFV-based ART partially explained the relationship between calendar year and visit 
frequency. After controlling for the proportion of patients receiving EFV-based ART, adjusted IRRs for 
the years 2016-2017 compared to years 2004-2007 changed from 0.68 (CI 0.68-0.69) to 0.74 (CI 0.73-
0.74) in programs using viral-load monitoring, from 0.61 (CI 0.60-0.61) to  0.88 (CI 0.87-0.89) in 
programs using CD4 monitoring, and from 0.69 (CI 0.69-0.70) to 0.77 (CI 0.76-0.78) in programs using 
clinical monitoring (Table S1) 
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Clinical stability and visit frequency 
Clinically stable patients were seen less frequently than patients receiving failing regimens. Pooled 
adjusted IRRs comparing visit rates for clinically stable patients with patients on failing ART were 0.82 
(95% CI 0.73-0.90) for patients classified based on the virological criterion, 0.81 (0.69-0.93) for 
patients classified based on the clinical criterion, and 0.90 (0.85-0.96) for patients classified based on 
the immunological criterion for clinical stability. Stable patients were seen less frequently than 
patients on failing regimens in all treatment programs, but as shown in Figure 2 the strength of the 
association varied considerably. 
Figure 3 shows the adjusted hazard rate of visits by criteria for clinical stability. Stable patients were 
seen less frequently than individuals on a failing ART regimen in programs using virological, 
immunological and clinical monitoring. However, absolute differences varied: differences were much 
larger for patients classified based on virological and clinical criteria than for patients classified based 
on the immunological criterion (about 0.5 visits compared to 2 visits per year). The same pattern was 
seen when we predicted the visit rate for other calendar years, treatment programs, or baseline CD4 
cell counts. 
Our results were not sensitive to the strategies for handling unscheduled treatment interruptions 
(i.e. exclusion or replacement with medians).  
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Discussion  
 
WHO has recently recommended longer visit intervals for clinically stable patients on ART,2 and 
countries have widely adopted differentiated ART delivery7–9 to ensure effectiveness and 
sustainability of HIV programs and to reduce the burden of care for patients and clinics.21–25 The 
frequency of visits is an important measure of the effectiveness of ART delivery and associations 
between criteria for clinical stability and visit frequency indicate the level of differentiation of visit 
intervals.26 In this study, we described trends in the frequency of visits between 2004 and 2017 in 10 
HIV programs in Southern Africa and examined associations between virological, immunological and 
clinical criteria for clinical stability and the rate of clinic visits. 
We observed a clear trend toward fewer visits in recent years that was independent of patients’ 
clinical and immunological stage at the start of ART. This trend was partially explained by the 
proportion of patients receiving EFV-based ART. The virological and clinical criteria for clinical 
stability were moderately associated with the rate of visits, but the immunological criterion for 
clinical stability and other patient characteristics including WHO stage at ART initiation, gender, and 
age were only weakly associated. The association of fewer visits among stable patients was 
consistently found across all treatment programs, but the strength of the association varied 
considerably. 
One possible explanation for time trends in visit frequency is that patients’ better health at the start 
of ART in recent years allowed programs to extend visit intervals. WHO progressively increased the 
CD4 cell count thresholds for ART eligibility, and the median CD4 cell count of patients at the start of 
ART increased substantially over the last decade.17,27–31 However, we adjusted our analysis for WHO 
clinical stage and CD4 cell count at ART initiation, and trends in visit frequency remained after 
controlling for these factors. Our data do not therefore support the hypothesis that trends in 
appointment spacing are driven by changes in ART eligibility criteria. We believe that other causes 
like the introduction of less toxic first-line regimens after 2010 and the widespread introduction of 
multi-month prescriptions were the drivers of the reduction in visit frequency.14,17,32 The finding that 
the trend towards fewer visits in recent years was partially explained by the proportion of patients 
receiving EFV-based ART supports our hypothesis that the introduction of less toxic first-line regimen 
were one of the reasons for the reduction in visit frequency.  
To implement differentiated ART delivery safely and effectively, programs need simple and reliable 
criteria for identifying clinically stable patients. Despite limited access to viral-load testing in several 
countries in this analysis, we see little evidence that programs were willing to use immunological 
criteria to differentiate visit intervals. In contrast, there was stronger evidence for differentiated 
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appointment spacing based on virological and clinical criteria. A recent study from Zambia confirms 
our finding of little differentiation of appointment intervals based on immunological criteria. For 
every 50 cells/µL increase in CD4 count, time between appointments increased by only one day.32 
Sensitivity and positive predictive value of immunological criteria for identifying individuals with 
virological treatment failure are low33 and caregivers may be reluctant to extend visit intervals based 
on these criteria as they may fear that virologically failing patients may not get the care they need. 
The need for simple criteria for clinical stability and continued on-site supervision and mentoring to 
strengthen adherence to guidelines is further reinforced by data from Malawi that suggest that 
differentiating appointment spacing based on a complex set of criteria may not be feasible.14 
According to Malawi’s national guidelines, patients are eligible for three-month ART refills if they 
meet the following criteria: 18 years or older, on first-line ART, no adverse drug reaction, no current 
illness or opportunistic infection, good adherence, and if viral-load testing was done then viral load 
<1000 copies/mL.13 A recent evaluation of differentiated ART delivery in Malawi shows that these 
criteria were not widely applied. A large proportion of eligible individuals did not receive three-
month ART refills, but many patients who were ineligible had been switched to extended refill 
intervals. In a large number of facilities, an equally large proportion of eligible and ineligible patients 
received three-month refills.14  
Our data suggest that caregivers are comfortably extending visit intervals for virologically suppressed 
patients. Viral load is a direct measure of treatment adherence and treatment efficacy that is easy to 
interpret and well trusted by healthcare workers. The study from Zambia showed that clinical 
stability is a highly transient state. Regimen switching, severe immunodeficiency, and new WHO 
Stage III/IV disease were common among patients who had reached clinical stability.32 Viral load 
enables early detection of treatment failure and early intervention.34,35 Despite additional costs for 
viral-load tests, differentiated care based on viral monitoring is a cost-effective strategy in low-
resource settings.22 However, scale-up of viral-load testing is complex and routine viral-load testing is 
not yet widely available in many resource limited settings,36,37and even where viral-load testing has 
been implemented, the results may not improve clinical management if not delivered in a timely 
manner or acted upon when making clinical decisions.34,38,39 
In the last decade, visit frequency has decreased substantially. Visits are anticipated to further 
decrease to six-month intervals as countries fully implement the WHO 2016 guidelines for 
differentiated care.2 Widespread implementation of the most recent guidelines only began in mid-
2016 and our study had insufficient follow-up time to explore the impact of the latest guideline 
change. Full implementation of the WHO 2016 guidelines has the potential to reduce the burden of 
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treatment for patients, improve retention in care, decongest clinics, and reduce costs.22,23,40 The 
clinical and public health impact of differentiated care is an important area for future evaluation. 
Our study included data from a broad range of treatment programs with different monitoring 
strategies and we could examine associations between virological, immunological, and clinical 
criteria for clinical stability and visit schedules. With long-term follow-up we could examine patterns 
in visit spacing from the beginning of the scale-up of ART in Africa until 2017. Among the study’s 
limitations, multi-month ART prescribing for stable patients on ART is a complementary approach to 
differentiated service delivery that is being increasingly adopted in sub-Saharan Africa.14,23 We also 
had insufficient data to distinguish between visits with clinical consultation and pharmacy refill visits 
without clinical consultation, and therefore could not evaluate the potential benefit of fewer clinical 
follow-up visits. We had insufficient data on adverse drug reactions and adherence, and could not 
consider these criteria in our definition of clinical stability. Although our study included data from a 
large number of urban and rural primary, secondary and tertiary facilities, the programs participating 
in IeDEA may not be representative of the national ART program in the different countries. Finally, 
we had little data on opportunistic infections after start of ART, and our definition of clinical stability 
in clinical monitoring programs relied solely on diagnoses of current tuberculosis. 
ART programs in Southern Africa reduced visit frequency over the last decade. Differences in visit 
rates between stable patients and patients failing ART were variable and modest overall. Because 
larger differences were seen particularly in programs using virological rather than immunological 
criteria for stability, we conclude that greater access to routine viral-load monitoring may increase 
scale-up of differentiated ART delivery.
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Table 1 Patient characteristics at initiation of antiretroviral therapy 
 Monitoring Strategy Total 
 Viral-load 
monitoring 
 CD4 
monitoring 
 Clinical 
monitoring 
Number of patients (%) 38,045 (21.0%)  85,555 (47.3%)  57,237 (31.7%) 180,837 (100.0%) 
Age (years)           
   16-24 2,228 (5.9%)  6,968 (8.1%)  5,376 (9.4%) 14,572 (8.1%) 
   25-34 15,861 (41.7%)  33,659 (39.3%)  21,337 (37.3%) 70,857 (39.2%) 
   35-49 16,610 (43.7%)  37,201 (43.5%)  23,457 (41.0%) 77,268 (42.7%) 
   50+ 3,346 (8.8%)  7,727 (9.0%)  7,067 (12.3%) 18,140 (10.0%) 
   Median (IQR) 35 (30-42)  35 (30-41)  35 (29-43) 35 (30-42) 
Gender           
   Male 12,731 (33.5%)  30,526 (35.7%)  20,340 (35.5%) 63,597 (35.2%) 
   Female 25,314 (66.5%)  55,029 (64.3%)  36,897 (64.5%) 117,240 (64.8%) 
Year of ART initiation           
   2004-2006 10,426 (27.4%)  11,275 (13.2%)  4,117 (7.2%) 25,818 (14.3%) 
   2007-2010 15,273 (40.1%)  37,999 (44.4%)  19,488 (34.0%) 72,760 (40.2%) 
   2011-2013 8,961 (23.6%)  22,883 (26.7%)  22,408 (39.1%) 54,252 (30.0%) 
   2014-2015 3,385 (8.9%)  13,136 (15.4%)  11,224 (19.6%) 27,745 (15.3%) 
   2016-2017 0 (0.0%)  262 (0.3%)  0 (0.0%) 262 (0.1%) 
WHO stage           
   1 15,459 (45.1%)  24,927 (32.1%)  8,735 (23.7%) 49,121 (33.0%) 
   2 3,625 (10.6%)  18,378 (23.7%)  8,784 (23.8%) 30,787 (20.7%) 
   3 10,907 (31.8%)  31,240 (40.2%)  16,368 (44.4%) 58,515 (39.3%) 
   4 4,288 (12.5%)  3,100 (4.0%)  2,998 (8.1%) 10,386 (7.0%) 
   Missing 3,766 (9.9%)  7,910 (9.2%)  20,352 (35.6%) 32,028 (17.7%) 
CD4 cell count (cells/µL)           
   <200 21,089 (72.5%)  38,095 (57.2%)  15,537 (52.7%) 74,721 (59.7%) 
   200-349 6,309 (21.7%)  20,178 (30.3%)  10,635 (36.1%) 37,122 (29.7%) 
   350-500 1,129 (3.9%)  5,164 (7.8%)  2,208 (7.5%) 8,501 (6.8%) 
   >500 567 (1.9%)  3,145 (4.7%)  1,094 (3.7%) 4,806 (3.8%) 
   Median (IQR) 136 (60-209)  179 (100-276)  190 (104-287) 171 (91-264) 
   Not measured 8,951 (23.5%)  18,973 (22.2%)  27,763 (48.5%) 55,687 (30.8%) 
Viral load (log10 copies/ml)           
   Median (IQR) 5 (4.4-5.5)  5 (4.4-5.5)  4.6 (3.3-5.3) 5 (4.4-5.5) 
   Not measured 30,699 (80.7%)  84,644 (98.9%)  56,686 (99.0%) 172,029 (95.1%) 
Data are number (percent) of patients if not stated otherwise. ART, antiretroviral therapy; IQR, interquartile range; WHO stage and CD4 cell 
count were assessed at initiation of ART.  
 
15 
 
Table 2 Predictors of visit frequency 
    Univariable analyses   Multivariable analyses 
  VL CD4 Clinical   VL CD4 Clinical 
    IRR (95% CI) IRR (95% CI) IRR (95% CI)   IRR (95% CI) IRR (95% CI) IRR (95% CI) 
Calendar year                 
   2004-2007   1 1 1   1 1 1 
   2008-2011   0.86 (0.85-0.86) 0.78 (0.77-0.79) 0.90 (0.89-0.91)   0.92 (0.91-0.92) 0.84 (0.83-0.84) 0.89 (0.88-0.90) 
   2012-2015   0.68 (0.67-0.68) 0.46 (0.46-0.47) 0.77 (0.76-0.78)   0.75 (0.75-0.76) 0.54 (0.54-0.55) 0.77 (0.76-0.78) 
   2016-2018   0.63 (0.62-0.64) 0.50 (0.50-0.51) 0.67 (0.66-0.68)   0.68 (0.68-0.69) 0.61 (0.60-0.61) 0.69 (0.69-0.70) 
Year on ART                 
   2   1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00)   1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00) 
   3   0.93 (0.93-0.94) 0.92 (0.92-0.93) 0.93 (0.93-0.93)   0.96 (0.96-0.96) 0.97 (0.96-0.97) 0.94 (0.94-0.95) 
   4   0.89 (0.89-0.89) 0.84 (0.83-0.84) 0.90 (0.90-0.91)   0.95 (0.94-0.95) 0.91 (0.91-0.92) 0.93 (0.93-0.94) 
   5+   0.81 (0.81-0.81) 0.68 (0.68-0.69) 0.84 (0.84-0.85)   0.92 (0.91-0.92) 0.84 (0.84-0.84) 0.90 (0.89-0.90) 
Age at ART initiation                 
   15-24   1 1 1   1 1 1 
   25-34   0.98 (0.96-0.99) 0.99 (0.97-1.00) 0.96 (0.95-0.97)   0.98 (0.96-0.99) 0.99 (0.98-1.00) 0.97 (0.96-0.98) 
   35-49   0.96 (0.94-0.97) 1.01 (1.00-1.03) 0.97 (0.96-0.98)   0.98 (0.96-0.99) 1.01 (1.00-1.02) 0.98 (0.97-0.99) 
   50+   0.96 (0.94-0.98) 1.04 (1.03-1.06) 1.04 (1.02-1.05)   1.00 (0.99-1.02) 1.04 (1.03-1.05) 1.01 (1.00-1.02) 
Gender                 
   Male   1 1 1   1 1 1 
   Female   1.01 (1.00-1.01) 0.98 (0.97-0.98) 1.04 (1.03-1.04)   1.01 (1.01-1.02) 0.99 (0.99-1.00) 1.03 (1.03-1.04) 
WHO clinical stage                 
   1   1 1 1   1 1 1 
   2   1.03 (1.02-1.04) 1.12 (1.11-1.13) 1.01 (1.00-1.02)   1.00 (0.99-1.01) 1.04 (1.03-1.04) 1.01 (1.00-1.02) 
   3   1.08 (1.07-1.09) 1.15 (1.14-1.16) 0.96 (0.95-0.97)   1.03 (1.02-1.04) 1.04 (1.03-1.05) 1.01 (1.01-1.02) 
   4   1.10 (1.08-1.11) 1.25 (1.23-1.27) 1.02 (1.00-1.03)   1.03 (1.02-1.04) 1.06 (1.05-1.07) 1.06 (1.04-1.07) 
   Unknown   1.62 (1.60-1.65) 1.10 (1.09-1.12) 0.85 (0.84-0.86)   1.03 (0.99-1.07) 1.06 (1.05-1.06) 1.00 (0.99-1.00) 
CD4 at ART initiation                 
   <200   1 1 1   1 1 1 
   200-349   0.90 (0.90-0.91) 0.89 (0.88-0.89) 1.04 (1.03-1.05)   0.96 (0.95-0.97) 0.94 (0.94-0.95) 1.01 (1.00-1.01) 
   350-500   0.89 (0.87-0.91) 0.84 (0.83-0.85) 1.06 (1.04-1.08)   0.96 (0.94-0.98) 0.92 (0.91-0.93) 1.00 (0.99-1.02) 
   >500   0.88 (0.86-0.91) 0.81 (0.80-0.82) 1.10 (1.08-1.13)   0.94 (0.92-0.95) 0.89 (0.87-0.90) 1.00 (0.98-1.02) 
   Unknown   1.02 (1.01-1.03) 0.90 (0.89-0.90) 0.95 (0.95-0.96)   0.99 (0.99-1.00) 0.96 (0.95-0.96) 1.01 (1.00-1.01) 
Data are incidence rate ratios (IRR) and 95% confidence intervals (CIs) from univariable and multivariable Poisson models. Clinical, Clinical 
monitoring; CD4, CD4 monitoring; VL, Viral-load monitoring. Calendar year and years since antiretroviral therapy (ART) initiation were 
assessed at each visit. CD4 cell count, WHO clinical stage, and age were measured at initiation of antiretroviral therapy (ART). Multivariable 
model is adjusted for all variables shown in the table and treatment program.  
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Figure 1 Flow of eligibility of patients 
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Figure 2 Forest plot of incidence-rate ratios comparing clinically stable patients and patients 
receiving failing regimens 
Forest plot of adjusted incidence-rate ratios (IRRs) comparing visit rates between clinically stable patients and patients receiving failing 
antiretroviral therapy (ART) regimens in 10 treatment programs in Southern Africa. Patients from programs using viral-load monitoring 
were classified based on a virological criterion for clinical stability, patients from programs using CD4 monitoring were classified based on 
an immunological criterion for clinical stability, and patients from programs using clinical monitoring were classified based on a clinical 
criterion for clinical stability. IRRs are adjusted for calendar year, time on ART, CD4 cell count, age, WHO clinical stage at ART initiation, and 
gender. Separate models were fitted for each treatment program and estimates were pooled by criterion for clinical stability using random 
effects meta-analysis. N, Number of patients in each treatment program at the beginning of follow-up (i.e. one year after initiation of ART). 
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Figure 3 Rate of visits by clinical stability 
Adjusted hazard rates of visits per year (solid lines) and 95% confidence intervals (dashed lines) for clinically stable patients and patients 
receiving failing ART regimens. Patients from programs using viral-load monitoring were classified based on a virological criterion for 
clinical stability, patients from programs using CD4 monitoring were classified based on a immunological criterion for clinical stability, and 
patients from programs using clinical monitoring were classified based on a clinical criterion for clinical stability. Models adjusted for 
clinical stability, calendar year, CD4 cell count at ART initiation, age, gender, and treatment program. Hazard rates were predicted for years 
2016-2017 for 25-34 years old female patients starting ART with a CD4 cell count of 200-349 cells/µL at the largest treatment program 
using the respective monitoring strategy. 
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Supplementary appendix 
Table S1: Predictors of visit frequency controlling for proportion of patients receiving efavirenz-
based antiretroviral therapy. 
  VL CD4 Clinical 
    IRR (95% CI) IRR (95% CI) IRR (95% CI) 
Univariable analyses   
   Proportion of patients receiving EFV     
      per 100% increase   0.39 (0.38-0.41) 0.31 (0.30-0.31) 0.86 (0.85-0.86) 
Multivariable analyses     
   Calendar year         
      2004-2007   1 1 1 
      2008-2011   0.92 (0.91-0.93) 0.93 (0.92-0.94) 0.90 (0.89-0.91) 
      2012-2015   0.78 (0.78-0.79) 0.71 (0.71-0.72) 0.81 (0.80-0.82) 
      2016-2018   0.74 (0.74-0.75) 0.88 (0.87-0.89) 0.77 (0.76-0.78) 
   Year on ART         
      2   1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00) 
      3   0.96 (0.96-0.96) 0.97 (0.96-0.97) 0.94 (0.94-0.95) 
      4   0.95 (0.94-0.95) 0.92 (0.91-0.92) 0.93 (0.93-0.94) 
      5+   0.92 (0.91-0.92) 0.86 (0.86-0.87) 0.91 (0.90-0.91) 
   Age at ART initiation         
      15-24   1 1 1 
      25-34   0.98 (0.97-0.99) 0.99 (0.98-1.00) 0.97 (0.96-0.98) 
      35-49   0.98 (0.97-0.99) 1.01 (1.00-1.02) 0.97 (0.96-0.98) 
      50+   1.00 (0.99-1.02) 1.04 (1.03-1.05) 1.01 (1.00-1.02) 
   Gender         
      Male   1 1 1 
      Female   1.01 (1.01-1.02) 0.99 (0.99-1.00) 1.03 (1.03-1.04) 
   WHO clinical stage         
      1   1 1 1 
      2   1.00 (0.99-1.02) 1.03 (1.02-1.03) 1.01 (1.00-1.02) 
      3   1.03 (1.02-1.03) 1.02 (1.02-1.03) 1.00 (1.00-1.01) 
      4   1.02 (1.01-1.03) 1.04 (1.03-1.05) 1.05 (1.03-1.06) 
      Unknown   1.04 (1.00-1.08) 1.06 (1.06-1.07) 0.99 (0.99-1.00) 
   CD4 at ART initiation         
      <200   1 1 1 
      200-349   0.96 (0.96-0.97) 0.95 (0.94-0.95) 1.01 (1.00-1.02) 
      350-500   0.96 (0.94-0.98) 0.93 (0.92-0.94) 1.01 (0.99-1.02) 
      >500   0.94 (0.92-0.96) 0.90 (0.89-0.91) 1.00 (0.98-1.02) 
      Unknown   0.99 (0.98-1.00) 0.97 (0.96-0.98) 1.01 (1.01-1.02) 
   Proportion of patients receiving EFV         
      per 100% increase   0.64 (0.62-0.66) 0.56 (0.55-0.57) 0.88 (0.88-0.89) 
Data are incidence rate ratios (IRR) and 95% confidence intervals (CIs) from univariable and multivariable Poisson models. Clinical, Clinical 
monitoring; CD4, CD4 monitoring; VL, Viral-load monitoring. Calendar year and years since antiretroviral therapy (ART) initiation were 
assessed at each visit. CD4 cell count, WHO clinical stage, and age were measured at initiation of antiretroviral therapy (ART). Proportion of 
patients receiving efavirenz (EFV)-based antiretroviral therapy regimen at a treatment program in calendar year. Multivariable model is 
adjusted for all variables shown in the table and treatment program.  
  
21 
 
Figure S1: Proportion of patients receiving efavirenz-based antiretroviral therapy. 
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